Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 B. pertussis human challenge study

Next Previous
Trial Profile

A Phase 3 B. pertussis human challenge study

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPZE 1 (Primary)
  • Indications Pertussis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 10 Feb 2026 According to an ILiAD Biotechnologies media release, the company announced the successful closing of an oversubscribed $115 million Series B financing.Proceeds to support Phase 3 development of BPZE1 with pivotal study to begin in 2026.
  • 10 Feb 2026 According to an ILiAD Biotechnologies media release, initial data expected in 2027.
  • 02 Dec 2025 According to an ILiAD Biotechnologies media release, the study is anticipated to begin next year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top